FDA Sodium Targets Show No Measurable Effect — What the New Analysis Actually Found

The headline number is zero. Five years after the FDA asked the food industry to voluntarily cut sodium, a new analysis presented at NUTRITION 2026 found no apparent reduction in the sodium content of the food supply. Here is what the research actually said, why the voluntary approach stalled, and the March 2026 modeling that shows even small mandatory cuts would save thousands of lives a year.

What Was Presented, and By Whom

At NUTRITION 2026 — the American Society for Nutrition's annual meeting, held July 25–28 in National Harbor, Maryland — researchers led by first author Kevin Kusnadi and senior author Dr. Matti Marklund of Johns Hopkins Bloomberg School of Public Health presented an analysis titled, without much room for interpretation, "No Apparent Reduction in Sodium Content after 2021 Issuance of FDA Voluntary Sodium Reduction Goals."

The context: in 2021 the FDA issued voluntary sodium-reduction targets for roughly 160 categories of processed and restaurant food, aiming to nudge average American intake — currently about 3,300 mg a day — toward the 2,300 mg ceiling that blood-pressure guidelines actually recommend. Phase II targets followed in August 2024. The new analysis examined what the food supply did in response to phase one, and found no apparent effect. As Marklund put it in the accompanying statement, the findings add to substantial evidence that voluntary, non-binding targets are a less effective approach, and that future efforts need stronger accountability mechanisms — "mandatory sodium targets with financial consequences for non-compliance." The FDA itself is expected to publish a formal evaluation of the phase I targets later in 2026 (the meeting's news release is here).

Read our way — the two-column way — nothing about this is surprising. Seventy percent of American sodium arrives inside processed, prepared and restaurant food. A policy that leaves the default plate unchanged leaves the sodium column unchanged, no matter what the shaker on the table does.

Why Voluntary Targets Stall

Salt is not in packaged food because executives love it; it is there because it is cheap, it binds water, it masks off-flavors, and — the awkward part — customers who grow up on it revolt when it disappears abruptly. A voluntary framework asks each company to move, but guarantees no competitor will have to move with it, and no consumer will reward the effort. The predictable result is what the analysis found: the targets existed on paper and the grams did not move.

The counterexample is instructive, because 2026 also delivered it. Two modeling studies in the March 2026 issue of the journal Hypertension looked at what happens when sodium actually does come down, quietly and across the board. France trimmed 17% to 35% of the sodium from baguettes and other bread staples starting in 2022 — the population never noticed — and the resulting population-wide blood-pressure shift is projected to cut annual heart-attack and stroke rates by about 1% each, saving more than a thousand lives a year. The UK analysis found that comparable changes across packaged food and takeout could cut average daily sodium by about 18%, preventing more than 100,000 heart-disease cases and 25,000 strokes over two decades. Small cuts, universal coverage, enormous arithmetic.

The March 2026 Evidence, in Numbers

The two modeling studies measure the upside of doing the thing the FDA asked for voluntarily — with enforcement:

The Potassium Counter-Move Is Getting Serious

The same month produced one more datapoint that fits this site's worldview uncomfortably well. A July 2026 report in the American Journal of Clinical Nutrition argued that sodium reduction and potassium addition should be designed together — not as separate campaigns — noting that potassium chloride can typically replace 25–30% of sodium chloride in a formulation before a metallic off-flavor shows up, and citing recent evidence that blood-pressure response to potassium-enriched salt shows essentially no between-person variability. In plain English: a potassium-enriched salt substitute appears to lower blood pressure in nearly everyone, which is about as strong as a population-level nutrition claim gets.

That is the direction serious policy discussion is now moving: instead of only asking the food supply to take something away, change the chemistry of what it puts back. For the American food supply — where the potassium column of the average day falls thousands of milligrams short of the ~4,700 mg DASH target — that is a two-column fix for a two-column problem.

What This Changes for Your Grocery Cart: Nothing Today

The honest consumer takeaway is that the policy floor is not coming to save the sodium column this year. The FDA's own phase I evaluation is expected later in 2026, and any mandatory regime — if it ever arrives — would phase in over years. Until then, the 140 mg-per-serving line on a nutrition panel is still the only enforcement mechanism in the aisle, and you are the enforcement mechanism. Our label-reading guide covers the five-second version; the aisle case files cover the specific shelves where the sodium hides.

We will keep tracking this file — the phase I evaluation lands later this year, and if it confirms the meeting analysis, the mandatory-targets debate gets very real. When it does, we will translate it the same way: what changed, by how much, and what it does to the two numbers on your plate.